BioMarin Pharmaceutical (BMRN) vs. Syros Pharmaceuticals (SYRS) Head-To-Head Survey

BioMarin Pharmaceutical (NASDAQ: BMRN) and Syros Pharmaceuticals (NASDAQ:SYRS) are both medical companies, but which is the better investment? We will compare the two companies based on the strength of their institutional ownership, analyst recommendations, risk, valuation, earnings, dividends and profitability.

Earnings and Valuation

This table compares BioMarin Pharmaceutical and Syros Pharmaceuticals’ revenue, earnings per share and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
BioMarin Pharmaceutical $1.12 billion 13.15 -$630.21 million ($0.90) -92.91
Syros Pharmaceuticals $320,000.00 1,199.94 -$47.74 million ($2.01) -7.26

Syros Pharmaceuticals has lower revenue, but higher earnings than BioMarin Pharmaceutical. BioMarin Pharmaceutical is trading at a lower price-to-earnings ratio than Syros Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Volatility and Risk

BioMarin Pharmaceutical has a beta of 1.82, meaning that its share price is 82% more volatile than the S&P 500. Comparatively, Syros Pharmaceuticals has a beta of -3.72, meaning that its share price is 472% less volatile than the S&P 500.

Analyst Ratings

This is a summary of recent ratings for BioMarin Pharmaceutical and Syros Pharmaceuticals, as reported by

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
BioMarin Pharmaceutical 0 6 16 0 2.73
Syros Pharmaceuticals 0 1 6 0 2.86

BioMarin Pharmaceutical presently has a consensus price target of $113.57, suggesting a potential upside of 35.82%. Syros Pharmaceuticals has a consensus price target of $26.14, suggesting a potential upside of 79.04%. Given Syros Pharmaceuticals’ stronger consensus rating and higher probable upside, analysts plainly believe Syros Pharmaceuticals is more favorable than BioMarin Pharmaceutical.


This table compares BioMarin Pharmaceutical and Syros Pharmaceuticals’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
BioMarin Pharmaceutical -12.45% -4.60% -3.09%
Syros Pharmaceuticals N/A -62.01% -55.65%

Insider & Institutional Ownership

99.3% of BioMarin Pharmaceutical shares are held by institutional investors. Comparatively, 58.0% of Syros Pharmaceuticals shares are held by institutional investors. 1.9% of BioMarin Pharmaceutical shares are held by company insiders. Comparatively, 33.6% of Syros Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.


BioMarin Pharmaceutical beats Syros Pharmaceuticals on 7 of the 13 factors compared between the two stocks.

About BioMarin Pharmaceutical

BioMarin Pharmaceutical Inc. is a biotechnology company. The Company develops and commercializes pharmaceuticals for various diseases and medical conditions. As of December 31, 2016, the Company’s therapy portfolio consisted of five products, and multiple clinical and pre-clinical product candidates. Its commercial products include Aldurazyme (laronidase) for Mucopolysaccharidosis I (MPS I), Firdapse (amifampridine phosphate) for Lambert Eaton Myasthenic Syndrome (LEMS), Kuvan (sapropterin dihydrochloride) for phenylketonuria (PKU), Naglazyme (galsulfase) for Mucopolysaccharidosis VI (MPS VI) and Vimizim (elosulfase alpha) for Mucopolysaccharidosis IV Type A (MPS IV A). The Company is conducting clinical trials on various product candidates for the treatment of various diseases. Its clinical product candidates include Brineura, pegvaliase, vosoritide, BMN 270 and BMN 250.

About Syros Pharmaceuticals

Syros Pharmaceuticals, Inc. is a biopharmaceutical company. The Company offers a gene control platform designed to analyze the unexploited region of deoxyribonucleic acid (DNA) in human disease tissue to identify and drug targets linked to genomically defined patient populations. The Company is focused on developing treatments for cancer and immune-mediated diseases and is building a pipeline of gene control medicines. The Company’s drug programs include SY-1425 (retinoic acid receptor alpha (RARa) agonist) and SY-1365 (cyclin-dependent kinase 7 (CDK7) inhibitor). SY-1425 (tamibarotene) is an oral, potent and selective agonist, or activator, of the transcription factor RARa. SY-1365 is a small molecule inhibitor of the transcriptional kinase known as CDK7. The Company is using its platform to analyze gene expression programs across additional cancers, inflammatory diseases and other diseases to identify optimal points of therapeutic intervention in specific subsets of patients.

What are top analysts saying about BioMarin Pharmaceutical Inc.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for BioMarin Pharmaceutical Inc. and related companies.


Leave a Reply

share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit